Therapeutic Appropriateness of Cariprazine in the Management of Schizophrenia: Experts' Opinion using a Delphi Approach.


Journal

Current neuropharmacology
ISSN: 1875-6190
Titre abrégé: Curr Neuropharmacol
Pays: United Arab Emirates
ID NLM: 101157239

Informations de publication

Date de publication:
2023
Historique:
received: 09 11 2022
revised: 06 01 2023
accepted: 13 01 2023
pmc-release: 01 03 2024
medline: 11 9 2023
pubmed: 20 7 2023
entrez: 20 7 2023
Statut: ppublish

Résumé

Schizophrenia is a psychiatric disorder whose therapeutic objectives are aimed at reducing symptoms and improving patient's quality of life. First- and second-generation antipsychotics present numerous side effects. Recently introduced in the treatment of schizophrenia, cariprazine has shown to improve positive and negative symptoms as well as cognitive impairment, with good tolerability. To assess the level of consensus among Italian psychiatrists in relation to the use of cariprazine in the treatment of schizophrenia by using the Delphi technique. A Delphi study was undertaken between January and July 2022. Two questionnaires were consecutively sent to a panel of 97 psychiatrists from all over Italy, of which 81 actively participated, anonymously, in at least one of the two consultations with a sufficiently high response rate (83%). Broad consensus in terms of the efficacy and safety of cariprazine in the treatment of schizophrenia during all phases of the disorder. The young first-episode schizophrenia patient with or without substance abuse seems to be an excellent candidate for cariprazine therapy. In addition, the lack of side effects makes cariprazine a suitable drug for adult and elderly patients with schizophrenia. However, there is still limited experience with the use of cariprazine, along with little knowledge of the most recent real-life data. These results could encourage wider dissemination of evidence-based practices with the final aim of optimizing the clinical use of cariprazine in patients with schizophrenia.

Sections du résumé

BACKGROUND BACKGROUND
Schizophrenia is a psychiatric disorder whose therapeutic objectives are aimed at reducing symptoms and improving patient's quality of life. First- and second-generation antipsychotics present numerous side effects. Recently introduced in the treatment of schizophrenia, cariprazine has shown to improve positive and negative symptoms as well as cognitive impairment, with good tolerability.
OBJECTIVE OBJECTIVE
To assess the level of consensus among Italian psychiatrists in relation to the use of cariprazine in the treatment of schizophrenia by using the Delphi technique.
METHOD METHODS
A Delphi study was undertaken between January and July 2022. Two questionnaires were consecutively sent to a panel of 97 psychiatrists from all over Italy, of which 81 actively participated, anonymously, in at least one of the two consultations with a sufficiently high response rate (83%).
RESULTS RESULTS
Broad consensus in terms of the efficacy and safety of cariprazine in the treatment of schizophrenia during all phases of the disorder. The young first-episode schizophrenia patient with or without substance abuse seems to be an excellent candidate for cariprazine therapy. In addition, the lack of side effects makes cariprazine a suitable drug for adult and elderly patients with schizophrenia. However, there is still limited experience with the use of cariprazine, along with little knowledge of the most recent real-life data.
CONCLUSION CONCLUSIONS
These results could encourage wider dissemination of evidence-based practices with the final aim of optimizing the clinical use of cariprazine in patients with schizophrenia.

Identifiants

pubmed: 37469149
pii: CN-EPUB-133025
doi: 10.2174/1570159X21666230719162023
pmc: PMC10556386
doi:

Substances chimiques

cariprazine F6RJL8B278
Antipsychotic Agents 0
Piperazines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2206-2216

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Références

NPJ Schizophr. 2021 Feb 15;7(1):11
pubmed: 33589645
Am J Psychiatry. 2020 Apr 1;177(4):342-353
pubmed: 31838873
Int Clin Psychopharmacol. 2017 Nov;32(6):319-328
pubmed: 28692485
Neuropsychiatr Dis Treat. 2021 Apr 07;17:957-970
pubmed: 33854317
Drugs. 2020 Nov;80(17):1763-1781
pubmed: 32930957
Neuropsychiatr Dis Treat. 2018 Oct 05;14:2563-2577
pubmed: 30323605
Front Psychiatry. 2020 Mar 03;11:61
pubmed: 32194443
Riv Psichiatr. 2019 Nov-Dec;54(6):11-15
pubmed: 32310934
Am J Psychiatry. 2020 Sep 1;177(9):868-872
pubmed: 32867516
Front Psychiatry. 2022 Jan 05;12:770234
pubmed: 35069278
Curr Top Med Chem. 2021 Oct 25;21(16):1500-1516
pubmed: 34218785
CNS Spectr. 2018 Feb;23(1):39-50
pubmed: 28478771
Riv Psichiatr. 2019 Nov-Dec;54(6):7-10
pubmed: 32310933
Riv Psichiatr. 2019 Nov-Dec;54(6):16-19
pubmed: 32310935
Neuropsychiatr Dis Treat. 2019 Jun 05;15:1525-1535
pubmed: 31239687
Front Psychiatry. 2022 Jan 25;12:781946
pubmed: 35145438
J Psychopharmacol. 2020 Jan;34(1):3-78
pubmed: 31829775
Riv Psichiatr. 2019 Nov-Dec;54(6):1-6
pubmed: 32310932
Psychopharmacol Bull. 2020 Sep 14;50(4):83-117
pubmed: 33012874
Clin Psychopharmacol Neurosci. 2021 Feb 28;19(1):174-178
pubmed: 33508803
Ther Adv Psychopharmacol. 2021 May 10;11:20451253211012250
pubmed: 34025981
J Clin Psychiatry. 2019 Jan 8;80(2):
pubmed: 30695290
Int J Psychiatry Clin Pract. 2017 Jun;21(2):82-90
pubmed: 28498090
CNS Drugs. 2020 May;34(5):473-507
pubmed: 32246399
Ann Gen Psychiatry. 2020 Sep 26;19:55
pubmed: 32999683
Int J Environ Res Public Health. 2021 Dec 19;18(24):
pubmed: 34948983
World J Methodol. 2021 Jul 20;11(4):116-129
pubmed: 34322364
Neuropsychiatr Dis Treat. 2021 Dec 07;17:3581-3588
pubmed: 34908838

Auteurs

Bernardo Dell'Osso (B)

Department of Mental Health and Addiction, University of Milan, ASST Fatebenefratelli-Sacco, Milan, Italy.
"Aldo Ravelli" Center for Nanotechnology and Neurostimulation, University of Milan, Milan, Italy.
Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.

Antonello Bellomo (A)

Department of Clinical and Experimental Medicine, Psychiatric Unit, University of Foggia, Foggia, Italy.

Andreas Pietro Maria Conca (AP)

NHS, National Health Service, Department of Mental Health, Bolzano, Italy.
Auxiliary University Department, Medical University of Innsbruck and Paracelsus Medizinische Privatuniversität (PMU), Salzburg, Austria.

Virginio Salvi (V)

Department of Clinical Neurosciences/DIMSC, Università Politecnica delle Marche, Ancona, Italy.

Alberto Siracusano (A)

Psychiatric Clinic, PTV Foundation - Policlinico Tor Vergata University of Rome, Rome, Italy.

Carmelo Zaffora (C)

NHS, National Health Service, Department of Mental Health, Azienda Sanitaria Provinciale (ASP 3), Catania, Italy.

Domenico De Berardis (D)

NHS, National Health Service, Department of Mental Health, ASL 4, Teramo, Italy.

Massimo Di Giannantonio (M)

Department of Neuroscience, Imaging and Clinical Sciences, University "G. d'Annunzio" of Chieti, Pescara, Chieti, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH